EGFR, HER2 and HER3 expression in primary colorectal carcinomas and corresponding metastases: Implications for targeted radionuclide therapy

Oncology Reports

Volumn 25, Issue 1, 2011, Pages 3-11

  Wei, Q ^a,b   Shui, Y ^a   Zheng, S ^a   Wester, K ^b   Nordgren, H ^c   Nygren, P ^c   Glimelius, B ^c,d   Carlsson, J ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cancer; Colorectal carcinoma; Epidermal growth factor receptor; HER2; HER3; Metastasis; Radionuclide; Receptor expression; Therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL MEMBRANE; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; SCORING SYSTEM; SIGNET RING CARCINOMA; STAINING; TARGETED RADIONUCLIDE THERAPY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RADIOISOTOPES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 78650734395     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00001035     Document Type: Article

References (66)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Ji BT, Devesa SS, Chow WH, Jin F, Gao YT, Colorectal cancer incidence trends by subsite in urban Shanghai. Cancer Epidemiol Biomarkers Prev., 7: 661-666, 1998.
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F and Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L and Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355: 1041-1047, 2000.
5. Carlsson J: EGFR-family expression and implications for targeted radionuclide therapy. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G, Carlsson J (eds). Springer Verlag, pp25-58, 2008.
6. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516, 2006.
7. Bublil EM and Yarden Y: The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19: 124-134, 2007.
8. Alekshun T and Garrett C: Targeted therapies in the treatment of colorectal cancers. Cancer Control 12: 105-110, 2005.
9. Beaven AW and Goldberg RM: Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow. Oncology (Williston Park) 20: 461-469, 2006.
10. De Luca A, Pignata S, Casamassimi A, D'Antonio A, Gridelli C, Rossi A, Cremona F, Parisi V, De Matteis A and Normanno N: Detection of circulating tumor cells in carcinoma patients by a novel epidermal growth factor receptor reverse transcription-PCR assay. Clin Cancer Res 6: 1439-1444, 2000.
11. Clarke LE, Leitzel K, Smith J, Ali SM and Lipton A: Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RTPCR. Int J Oncol 22: 425-430, 2003.
12. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV and Lenz HJ: Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer 6: 214-218, 2006.
13. Hynes NE and Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354, 2005.
14. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006.
15. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006. (Pubitemid 44142736)
16. Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H and Carlsson J: EGFR, HER2 and HER3 expression in laryngeal primary tumours and corresponding metastases. Ann Surg Oncol 15: 1193-1201, 2008.
17. Wei Q, Chen L, Sheng L, Nordgren H, Wester K and Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 31: 493-499, 2007.
18. Ekberg T, Nestor M, Engström M, Nordgren H, Wester K, Carlsson J and Anniko M: Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol 26: 1177-1185, 2005.
19. Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D and Economopoulos T: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6: 46, 2006.
20. Ljuslinder I, Malmer B, Isaksson-Mettävainio M, Oberg A, Henriksson R, Stenling R and Palmqvist R: ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases. Anticancer Res 29: 1489-1494, 2009.
21. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G and van de Vijver M: Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 16: 173-182, 2003.
22. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ and Davis NL: Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1: 97-105, 1992.
23. Porebska I, Harlozinska A and Bojarowski T: Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 21: 105-115, 2000.
24. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majo J, Benavente S, Armengol M and de Torres I, Grupo Espanol de Investigacion Clinica en Oncologia Radioterapica (GICOR). The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 74: 101-108, 2005.
25. Lee JC, Wang ST, Chow NH and Yang HB: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38: 1065-1071, 2002.
26. Resnick MB, Routhier J, Konkin T, Sabo E and Pricolo VE: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10: 3069-3075, 2004.
27. Giralt J, Eraso A, Armengol M, Rossello J, Majo J, Ares C, Espin E, Benavente S and de Torres I: Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54: 1460-1465, 2002.
28. Saeki T, Salomon DS, Johnson GR, Gullick WJ, Mandai K, Yamagami K, Moriwaki S, Tanada M, Takashima S and Tahara E: Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn J Clin Oncol 25: 240-249, 1995.
29. De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ and De Vries EG: Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 28: 971-979, 1998.
30. Goldstein NS and Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331-1346, 2001.
31. Italiano A, Saint-Paul MC, Caroli-Bosc FX, Francois E, Bourgeon A, Benchimol D, Gugenheim J and Michiels JF: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 16: 1503-1507, 2005.
32. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, Gerald W and Chen B: Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18: 1350-1356, 2005.
33. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G and Cascinu S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4772-4778, 2004.
34. Bralet MP, Paule B, Adam R and Guettier C: Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J Clin Oncol 23: 5844-5845, 2005.
35. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G and Cascinu S: Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. Br J Cancer 97: 92-97, 2007.
36. Dursun A, Poyraz A, Suer O, Sezer C and Akyol G: Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res 7: 24-27, 2001.
37. Koeppen HK, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, Sliwkowski MX and Hillan KJ: Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology 38: 96-104, 2001.
38. McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J and McLeod HL: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38: 2258-2264, 2002.
39. Knosel T, Petersen S, Schwabe H, Schluns K, Stein U, Schlag PM, Dietel M and Petersen I: Incidence of chromosomal imbalances in advanced colorectal carcinomas and their metastases. Virchows Arch 440: 187-194, 2002.
40. Nathanson DR, Culliford AT IV, Shia J, Chen B, D'Alessio M, Zeng ZS, Nash GM, Gerald W, Barany F and Paty PB: HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105: 796-802, 2003.
41. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB and Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol 27: 225-228, 2005.
42. Pavlakis K, Kountourakis P, Stathopoulos E, Psyrri A, Rontogianni D, Kafousi M, Derivianaki M, Xiros N, Pectasides D and Economopoulos T: Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol 15: 441-445, 2007.
43. Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H and Blomqvist C: HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br J Cancer 90: 2344-2348, 2004.
44. Wester K, Sjöström A, delaTorre M, Carlsson J and Malmström PU: HER-2: A possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 41: 282-288, 2002.
45. Gardmark T, Wester K, DeLa Torre M, Carlsson J and Malmström PU: Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. Br J Urol 95: 982-986, 2005. (Pubitemid 40655692)
46. Ciardiello F, Kim N, Saeki T, Dono R, Persico MG, Plowman GD, Garrigues J, Radke S, Todaro GJ and Salomon DS: Differential expression of epidermal growth factor-related proteins in human colorectal tumors. Proc Natl Acad Sci USA 88: 7792-7796, 1991.
47. Maurer CA, Friess H, Kretschmann B, Zimmermann A, Stauffer A, Baer HU, Korc M and Buchler MW: Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29: 771-777, 1998.
48. Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K and Spaventi R: Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126: 205-211, 2000.
49. Gusterson B, Cowley G, Smith JA and Ozanne B: Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 8: 649-658, 1984.
50. Damjanov I, Mildner B and Knowles BB: Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 55: 588-592, 1986.
51. Carlsson J, Stigbrand T and Adams GP: Introduction to radionuclide therapy. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G, Carlsson J (eds). Springer Verlag, pp1-11, 2008.
52. Winder T and Lenz HJ: Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev, April 2, 2010 (Epub ahead of print).
53. Ramos FJ, Macarulla T, Capdevila J, Elez E and Tabernero J: Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer. Clin Colorectal Cancer 7 (Suppl 2): S52-S57, 2008.
54. Ibrahim EM, Zekri JM and Bin Sadiq BM: Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis 25: 713-721, 2010.
55. Morgillo F, Cantile F, Fasano M, Troiani T, Martinelli E and Ciardiello F: Resistance mechanisms of tumour cells to EGFR inhibitors. Clin Transl Oncol 11: 270-275, 2009.
56. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, Cheng H and Ajani JA: Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 115: 3609-3617, 2009.
57. Waldner MJ and Neurath MF: The molecular therapy of colorectal cancer. Mol Aspects Med 31: 171-178, 2010.
58. Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A and Siena S: Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 5: 19-28, 2010.
59. Milano G, Etienne-Grimaldi MC, Dahan L, Francoual M, Spano JP, Benchimol D, Chazal M, Letoublon C, André T, Gilly FN, Delpero JR and Formento JL: Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19: 2033-2038, 2008.
60. Ljuslinder I, Melin B, Henriksson ML, Oberg A and Palmqvist R: Increased EGFR expression at the invasive margin is a negative prognostic factor in colorectal cancer. Int J Cancer, July 15, 2010 (Epub ahead of print).
61. Frejd FY: Novel alternative scaffolds and their potential use for tumor targeted radionuclide therapy. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G, Carlsson J (eds). Springer Verlag, pp89-116, 2008.
62. Friedman M, Nordberg E, Hoiden-Guthenberg I, Brismar H, Adams GP, Nilsson FY, Carlsson J and Stahl S: Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. Protein Eng Des Sel 20: 189-199, 2007.
63. Adams GP: Antibody fragments produced by recombinant and proteolytic methods. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G, Carlsson J (eds). Springer Verlag, pp77-88, 2008.
64. Fondell A, Edwards K, Ickenstein LM, Sjöberg S, Carlsson J and Gedda L: Nuclisome -A novel concept for radionuclide therapy using targeting liposomes. Eur J Nucl Med Mol Imaging 37: 114-123, 2010.
65. Tolmachev V: Choice of radionuclides and radiolabelling techniques. In: Targeted Radionuclide Tumor Therapy, Biological Aspects. Stigbrand T, Adams G, Carlsson J (eds). Springer Verlag, pp145-174, 2008.
66. Carlsson J, Steffen AC, Sundberg AL, Wikström M, Orlova A, Gedda L, Stenerlow B, Lundqvist H and Tolmachev V: Targeting EGFR and HER2 with 211-At-labeled molecules. Unexpected and expected dose-effect relations in cultured tumor cells. Curr Radiopharm 1: 225-233, 2008.